Feb 28, 2019

Lupin launches Generic Ranolazine ER Tablets in U.S.

Pharma major Lupin announced the exclusive launch of its Ranolazine Extended-Release (ER) Tablets, 500mg and 1000mg.

Lupin’s Ranolazine ER Tablets, 500mg and 1000mg are a generic version of Gilead Sciences, Inc.’s Ranexa ER Tablets, 500mg and 1000mg. Ranolazine is indicated for the treatment of chronic angina.

Ranolazine ER Tablets, 500mg and 1000mg had an annual sales of approximately USD 945 million in the US (IQVIA MAT December 2018).

Commenting on the launch, Mr. Nilesh Gupta, Managing Director, Lupin Limited said, “We are excited about the launch of generic Ranolazine as an exclusive generic in the US. This is a meaningful product and further strengthens our portfolio of generic products in the US. Launching exclusive and semi-exclusive generics is an important stepping stone as we transition to more complex generics. Products like Ranolazine bring significant savings to US consumers and are a key part of our vision to bring exclusive high quality, affordable medicines to market.”

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 8th largest generics pharmaceutical company in terms of market capitalization (28th December 2018, Bloomberg) and the 8th largest generics pharmaceutical company in terms of revenues (30th September 2018, Bloomberg LTM) globally. The Company is the 3rd largest pharmaceutical player in the US by prescriptions for the Total Market (IQVIA MAT December 2018); 3rd largest Indian pharmaceutical company by global revenues (30th September 2018, Bloomberg LTM); 6th largest generic pharmaceutical player in Japan (IQVIA MAT December 2018) and 5th largest company in the Indian Pharmaceutical Market (IQVIA MAT December 2018).

For the financial year ended 31st March, 2018, Lupin’s Consolidated sales and Net profits before exceptional items were at Rs. 155,598 million (USD 2.41 billion) and Rs. 13,934 million (USD 216 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries please contact –

Pooja Thakran
VP – Corporate Communications
Email: poojathakran@lupin.com
Ph: +91-22-66402531 / 8291013225

Arvind Bothra
Head – Investor Relations
Email:arvindbothra@lupin.com
Ph: +91-22-66408237
*Safe Harbor Statement

Ranexa® is a registered trademark of Gilead Sciences, Inc.

Market Buzz

Jun 03, 2019 PrimeCare® Integrates MedTek21® to Offer Facility-based Genomic Testing
May 22, 2019 Letco Med Announces the Launch of a New Industry-Leading Website and E-Commerce ...
May 17, 2019 MEDISCA Granted Planetary Mixing Patent and Exclusive Distribution Agreement
May 02, 2019 Transaction Data Systems (TDS) Delivers Smarter Approach to Claim Reconciliation
Apr 22, 2019 Visante healthcare consulting firm announces Judi Jacobi, PharmD, to join consul...
Apr 17, 2019 As an aging population demands more efficient pharmacy solutions, the founder of...
Apr 17, 2019 Adam Wallace Named Chief Technology Officer at Transaction Data Systems (TDS)
Apr 15, 2019 PharmaLink to Exhibit at 2019 Asembia Specialty Pharmacy Summit
Apr 04, 2019 Transaction Data Systems (TDS) Announces Acquisition of Pharm Assess, Inc.
Apr 01, 2019 Chad Collins Named President of Akro-Mils and Jamco Products
Mar 22, 2019 Tutela Welcomes Octapharma Plasma
Mar 18, 2019 Verity Solutions Recognized as Category Leader for 340B Management Systems in 20...
Mar 07, 2019 Stormont Vail Health Partners with Omnicell to Enhance Medication Management Str...
Mar 06, 2019 Rebranding Focuses ALG Mission - Combining Our Best to Bring You Our Best
Mar 04, 2019 RXinsider Celebrates 20 Years, 1999 - 2019
Feb 28, 2019 Lupin launches Generic Ranolazine ER Tablets in U.S.
Feb 18, 2019 QS/1® Offers Compliance Packaging Label Solution
Feb 15, 2019 QS/1 Partnership Offers Compliant Patient Communications
Feb 14, 2019 RXinsider is Proud to Welcome our Newest Partners!
Feb 12, 2019 Albertsons Companies Pharmacies Adopt TemperPack's ClimaCell™ Packaging
Feb 07, 2019 Fagron Launches New Brand Identity and Purpose
Feb 07, 2019 Medicine-On-Time has come together with Clinical Support Services, a leader in M...
Feb 04, 2019 Letco Med and Ananda Professional Partner to Bring CBD and Education to Compound...
Jan 30, 2019 Texas Children’s Hospital Expands Partnership with Omnicell
Jan 16, 2019 Helmer Scientific Launches the First Professional Medical-grade Refrigerators
Jan 15, 2019 The Compliance Team™ celebrates 25 years of accreditation transformation
Jan 11, 2019 CORE Higher Education Group partners with Pharmacists Mutual
Jan 10, 2019 SCA Pharma Awarded National Outsourced I.V. Admixture Services Agreement with Pr...
Jan 08, 2019 Tutela Welcomes the Center for Organ Recovery and Education
Dec 13, 2018 PharmaLink Launches Updated Website

RXinsider Product Overview Videos